Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Antimicrob Chemother ; 74(6): 1713-1717, 2019 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-30789210

RESUMO

OBJECTIVES: Tropheryma whipplei has been detected in 3.5% of the blood culture-negative cases of endocarditis in Spain. Experience in the management of T. whipplei endocarditis is limited. Here we report the long-term outcome of the treatment of previously reported patients who were diagnosed with infective endocarditis (IE) caused by T. whipplei from the Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) and discuss potential options for antimicrobial therapy for IE caused by T. whipplei. PATIENTS AND METHODS: Seventeen patients with T. whipplei endocarditis were recruited between 2008 and 2014 in 25 Spanish hospitals. Patients were classified according to the therapeutic regimen: ceftriaxone and trimethoprim/sulfamethoxazole, doxycycline + hydroxychloroquine and other treatment options. RESULTS: Follow-up data were obtained from 14 patients. The median follow-up was 46.5 months. All patients completed the antibiotic treatment prescribed, with a median duration of 13 months. Six patients were treated with ceftriaxone and trimethoprim/sulfamethoxazole (median duration 13 months), four with doxycycline + hydroxychloroquine (median duration 13.8 months) and four with other treatment options (median duration 22.3 months). The follow-up after the end of the treatments was between 5 and 84 months (median 24 months). CONCLUSIONS: All treatment lines were effective and well tolerated. Therapeutic failures were not detected during the treatment. None of the patients died or experienced a relapse during the follow-up. Only six patients received antibiotic treatment in accordance with guidelines. These data suggest that shorter antimicrobial treatments could be effective.


Assuntos
Antibacterianos/uso terapêutico , Endocardite Bacteriana/tratamento farmacológico , Endocardite Bacteriana/microbiologia , Tropheryma/efeitos dos fármacos , Tropheryma/fisiologia , Idoso , Antibacterianos/farmacologia , Quimioterapia Combinada , Endocardite Bacteriana/epidemiologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Espanha , Resultado do Tratamento
3.
Am J Trop Med Hyg ; 89(6): 1203-5, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24166040

RESUMO

The first confirmed case of Rickettsia parkeri infection in Uruguay is reported. To date, in South America, molecularly confirmed cases of human infection have been found in Argentina and probably, Brazil. Our patient returned to Spain after a 7-day trip to Colonia Suiza (Southwestern Uruguay). He presented fever (39°C), chills, and two eschars (tache noire-like) surrounded by an indurated, erythematous halo on the inner side of the left ankle besides a maculopapular rash on the legs. After treatment with doxycycline for 7 days, he fully recovered. R. parkeri infection was diagnosed by molecular-based detection of the microorganism in a swab specimen of the eschar. Diagnosis was supported by seroconversion between acute- and convalescent-phase sera specimens.


Assuntos
Antibacterianos/uso terapêutico , Doxiciclina/uso terapêutico , Infecções por Rickettsia/diagnóstico , Rickettsia/isolamento & purificação , Anticorpos Antibacterianos/sangue , Primers do DNA/genética , Febre , Humanos , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Rickettsia/classificação , Rickettsia/genética , Rickettsia/imunologia , Infecções por Rickettsia/tratamento farmacológico , Infecções por Rickettsia/microbiologia , Espanha , Viagem , Resultado do Tratamento , Uruguai
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA